Implication of bisphosphonate use in the treatment of SAPHO syndrome: Case report and discussion of current literature

Journal of Medical Hypotheses and Ideas

Volumn 9, Issue 2, 2015, Pages 72-78

  Gorecki, Patricia ^a   Stockmann, Philipp ^b   Distler, Jörg H W ^b   Wuest, Wolfgang ^b   Schmidt, Daniela ^b   Neukam, Friedrich Wilhelm ^b   Nkenke, Emeka ^b,c   Wehrhan, Falk ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bisphosphonates; Diffuse sclerosing osteomyelitis; SAPHO syndrome; Spondyloarthropathy; Zoledronate

Indexed keywords

CLINDAMYCIN; CORTICOSTEROID; ZOLEDRONIC ACID;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BONE BIOPSY; BONE LESION; BONE MARROW EDEMA; BONE SCINTISCANNING; CASE REPORT; CHILD; CHRONIC INFLAMMATION; DENTAL PROCEDURE; DENTAL SPLINT; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; FEVER; HUMAN; HUMAN TISSUE; JAW PAIN; MOLAR TOOTH; MOUTH EXAMINATION; MYOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOPANTOMOGRAM; OSTEITIS; OSTEOMYELITIS; PREMOLAR TOOTH; PUSTULOSIS PALMOPLANTARIS; RELAPSE; SACROILIITIS; SAPHO SYNDROME; SCHOOL CHILD; SPINAL PAIN; TOOTH EXTRACTION;

EID: 84945574979     PISSN: 22517294     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmhi.2015.04.002     Document Type: Article

References (31)

1. Chamot A.M., Benhamou C.L., Kahn M.F., Beraneck L., Kaplan G., Prost A. L syndrome acne pustulose hyperostose osteite (SAPHO). Resultats d'une enquete nationale; 85 observations. Rev Rhum Mal Osteoartic 1987, 54:187-196.
2. Reichardt L.F., Pitak-Arnnop P., Hemprich A., Dhanuthai K., Pausch N.C. Chronic refractory osteomyelitis as a part of synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome: a diagnostic challenge. ANZ J Surg 2011, 81(9):642-643.
3. Kopterides P., Pikazis D., Koufos C. Successful treatment of SAPHO syndrome with zoledronic acid. Arthritis Rheum 2004, 50(9):2970-2973.
4. Zemann W., Pau M., Feichtinger M., Ferra-Matschy B., Kaercher H. SAPHO syndrome with affection of the mandible: diagnosis, treatment, and review of literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011, 111(2):190-195.
5. Matzaroglou Ch., Velissaris D., Karageorgos A., Marangos M., Panagiotopoulos E., Karanikolas M. SAPHO syndrome diagnosis and treatment: report of five cases and review of the literature. Open Orthop J 2009, 5(3):100-106.
6. Olivieri I., Padula A., Palazzi C. Pharmacological management of SAPHO syndrome. Expert Opin Invest Drugs 2006, 15(10):1229-1233.
7. Amital H., Applbaum Y.H., Aamar S., Daniel N., Rubinow A. SAPHO syndrome treated with pamidronate: an open-label study of 10 patients. Rheumatology (Oxford) 2004, 43(5):658-661.
8. Boutin R.D., Resnick D. The SAPHO syndrome: an evolving concept for unifying several idiopathic disorders of bone and skin. Am J Roentgenol 1998, 170(3):585-591.
9. Mochizuki Y., Omura K., Hirai H., Kugimoto T., Osako T., Taguchi T. Chronic mandibular osteomyelitis with suspected underlying synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome: a case report. J Inflamm Res 2012, 5:29-35.
10. Kahn M.F., Khan M.A. The SAPHO syndrome. Baillieres Clin Rheumatol 1994, 8(2):333-362.
11. Hayem G., Bouchaud-Chabot A., Benali K., Roux S., Palazzo E., Silbermann-Hoffman O., et al. SAPHO syndrome: a long-term follow-up study of 120 cases. Semin Arthritis Rheum 1999, 29(3):159-171.
12. Suei Y., Taguchi A., Tanimoto K. Diagnostic points and possible origin of osteomyelitis in synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome: a radiographic study of 77 mandibular osteomyelitis cases. Rheumatology (Oxford) 2003, 42(11):1398-1403.
13. Compeyrot-Lacassagne S., Rosenberg A.M., Babyn P., Laxer R.M. Pamidronate treatment of chronic noninfectious inflammatory lesions of the mandible in children. J Rheumatol 2007, 34(7):1585-1589.
14. Hatano H., Shigeishi H., Higashikawa K., Shimasue H., Nishi H., Oiwa H., et al. A case of SAPHO syndrome with diffuse sclerosing osteomyelitis of the mandible treated successfully with prednisolone and bisphosphonate. J Oral Maxillofac Surg 2012, 70(3):626-631.
15. Orestes-Cardoso S., Nefussi J.R., Lezot F., Oboeuf M., Pereira M., Mesbah M., et al. Msx1 is a regulator of bone formation during development and postnatal growth: in vivo investigation in a transgenic mouse model. Connect Tissue Res 2002, 43(2-3):153-160.
16. Kerrison C., Davidson J.E., Cleary A.G., Beresford M.W. Pamidronate in the treatment of childhood SAPHO syndrome. Rheumatology (Oxford) 2004, 43(10):1246-1251.
17. Schultze-Mosgau S., Reich R.H. Assessment of inferior alveolar and lingual nerve disturbances after dentoalveolar surgery, and of recovery of sensitivity. Int J Oral Maxillofac Surg 1993, 22(4):214-217.
18. Hamdy R.C. Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass. Drug Des Dev Ther 2010, 18(4):321-335.
19. Kirchhoff T., Merkesdal S., Rosenthal H., Prokop M., Chavan A., Wagner A., et al. Diagnostic management of patients with SAPHO syndrome: use of MR imaging to guide bone biopsy at CT for microbiological and histological work-up. Eur Radiol 2003, 13(10):2304-2308.
20. Colina M., Lo Monaco A., Khodeir M., Trotta F. Propionibacterium acnes and SAPHO syndrome: a case report and literature review. Clin Exp Rheumatol 2007, 25:457-460.
21. Assmann G., Kueck O., Kirchhoff T., Rosenthal H., Voswinkel J., Pfreundschuh M., et al. Efficacy of antibiotic therapy for SAPHO syndrome is lost after its discontinuation: an interventional study. Arthritis Res Ther 2009, 11(5):R140.
22. Roldán J.C., Terheyden H., Dunsche A., Kampen W.U., Schroeder J.O. Acne with chronic recurrent multifocal osteomyelitis involving the mandible as part of the SAPHO syndrome: case report. Br J Oral Maxillofac Surg 2001, 39(2):141-144.
23. Ben Abdelghani K., Dran D.G., Gottenberg J.E., Morel J., Sibilia J., Combe B. Tumor necrosis factor-alpha blockers in SAPHO syndrome. J Rheumatol 2010, 37(8):1699-1704.
24. Karmakar S., Kay J., Gravallese E.M. Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. Rheum Dis Clin North Am 2010, 36(2):385-404.
25. Moon S.J., Ahn I.E., Jung H., Yi H., Kim J., Kim Y., et al. Temporal differential effects of proinflammatory cytokines on osteoclastogenesis. Int J Mol Med 2013, 31(4):769-777.
26. Geusens P. The role of RANK ligand/osteoprotegerin in rheumatoid arthritis. Ther Adv Musculoskelet Dis 2012, 4(4):225-233.
27. Wehrhan F., Hyckel P., Ries J., Stockmann P., Nkenke E., Schlegel K.A., et al. Expression of Msx-1 is suppressed in bisphosphonate associated osteonecrosis related jaw tissue-etiopathology considerations respecting jaw developmental biology-related unique features. J Transl Med 2010, 13(8):96.
28. Wehrhan F., Hyckel P., Amann K., Ries J., Stockmann P., Schlegel K., et al. Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment. Oral Dis 2011, 17(4):433-442.
29. Rodríguez-Vázquez J.F., Verdugo-López S., Garrido J.M., Murakami G., Kim J.H. Morphogenesis of the manubrium of sternum in human embryos: a new concept. Anat Rec (Hoboken) 2013, 296(2):279-289.
30. Solau-Gervais E., Soubrier M., Gerot I., Grange L., Puechal X., Sordet C., et al. The usefulness of bone remodelling markers in predicting the efficacy of pamidronate treatment in SAPHO syndrome. Rheumatology (Oxford) 2006, 45(3):339-342.
31. Colina M., La Corte R., Trotta F. Sustained remission of SAPHO syndrome with pamidronate: a follow-up of fourteen cases and a review of the literature. Clin Exp Rheumatol 2009, 27(1):112-115.